EMBC - Embecta Corp.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Parsippany,
United States
Type: Equity
EMBC price evolution
EMBC
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $206.4 | $159.1 | $190.1 | $152.7 |
| Inventory | $149.2 | $152.1 | $170.3 | $157.6 |
| Total current assets | $719.5 | $749.1 | $787.5 | $756.3 |
| Long term investments | ||||
| Property, plant & equipment | $323 | $323.2 | $329.7 | $332 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $1217.8 | $1214.4 | $1252.1 | $1210 |
| Current liabilities | ||||
| Accounts payable | $42.1 | $53.5 | $56.1 | $52.5 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $326.6 | $353.5 | $385.8 | $357.7 |
| Long term debt | $1624 | $1625.4 | $1626.8 | $1628 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $2011.3 | $2036.1 | $2061.5 | $2032.6 |
| Shareholders' equity | ||||
| Retained earnings | -$530 | -$541.1 | -$538.5 | -$545.1 |
| Other shareholder equity | -$297.5 | -$309.1 | -$294.7 | -$296.2 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 30 Oct 2022 | 29 Oct 2021 | 30 Oct 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $160.3 | $22.2 | $151 | $120 |
| Inventory | $152.1 | $122.8 | $118 | $102 |
| Total current assets | $749.1 | $664.7 | $292 | $235 |
| Long term investments | ||||
| Property, plant & equipment | $323.2 | $307.9 | $455 | $467 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $1214.4 | $1086.4 | $788 | $738 |
| Current liabilities | ||||
| Accounts payable | $53.5 | $41.4 | $54 | $50 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $353.5 | $301 | $164 | $137 |
| Long term debt | $1625.4 | $1630.7 | ||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $2036.1 | $1977.8 | $194 | $166 |
| Shareholders' equity | ||||
| Retained earnings | -$541.1 | -$577.1 | ||
| Other shareholder equity | -$309.1 | -$324.9 | $594 | $572 |
| Total shareholder equity | ||||
| (in millions $) | 30 Jul 2022 | 30 Apr 2022 | 31 Jan 2022 | 29 Oct 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $291.1 | $274.5 | $289.3 | $1165 |
| Cost of revenue | ||||
| Gross Profit | $203.1 | $191.2 | $203.9 | $800 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $96.1 | $92.3 | $87.3 | $308 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $11.2 | $14.3 | $17.8 | $80 |
| Interest expense | -$19.5 | -$4.9 | ||
| Net income | ||||
| Net income | $62.4 | $79.6 | $98.8 | $415 |
| Income (for common shares) | ||||
| (in millions $) | 29 Oct 2021 | 30 Oct 2020 | 30 Oct 2019 | |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1165 | $1086 | $1109 | |
| Cost of revenue | ||||
| Gross Profit | $800 | $763 | $786 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $308 | $276 | $284 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $80 | $58 | $68 | |
| Interest expense | ||||
| Net income | ||||
| Net income | $415 | $428 | $432 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Jul 2022 | 30 Apr 2022 | 31 Jan 2022 | 29 Oct 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$15.4 | -$10.1 | -$4.3 | -$39 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$40.9 | -$44.2 | -$134.5 | -$417 |
| Effect of exchange rate | -$5.6 | -$2.8 | ||
| Change in cash and equivalents | $292.3 | $264.3 | ||
| (in millions $) | 29 Oct 2021 | 30 Oct 2020 | 30 Oct 2019 | |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$39 | -$42 | -$69 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$417 | -$457 | -$436 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | ||||
News
Fundamentals
| Market cap | $819.85M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 57.57M |
| Revenue | $2.02B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $655.80M |
| Revenue Q/Q | 2.03% |
| Revenue Y/Y | 607.99% |
| P/E ratio | 1.25 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 0.41 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | $11.39 |
|---|---|
| ROA | 53.60% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.20 |
| Quick ratio | 1.75 |